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SHORT COMMUNICATION
Melphalan transport into human malignant lymphoid cells differs from
the murine equivalent in vitro
B.C. Millar, J.A. Maitland, J.L. Millar & J.B.G. Bell
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, UK.
Although melphalan is used extensively as a single agent in
the treatment of multiple myeloma, myelosuppression limits
the dose of drug used in man particularly in circumstances
which cannot include autologous bone marrow trans-
plantation (McElwain & Powles, 1983; Selby et al., 1987,
1988).
Melphalan uptake is mediated by at least two separate
amino acid transport systems in murine tumour cells in vitro
(Begleiter et al., 1979; Goldeburg et al., 1979). One system
(L) is inhibited by 2-aminobicyclo-(2,2,1)-heptane-2-
carboxylic acid (BCH), a synthetic L-amino acid, and L-
leucine. The second transport system is insensitive to BCH
and oa-aminoisobutyric acid, an analogue of alanine, and also
has high affinity for L-leucine (Vistica, 1980). The finding
that melphalan is transported into normal murine haemo-
poietic cells (GM-CFUJ) by the BCH-insensitive transport
system in vitro prompted the synthesis of analogues of
nitrogen mustard that are transported by the high affinity
BCH-sensitive transport system (Ahmad et al., 1986). Pre-
liminary data in mouse L1210 cells in vitro showed that one
such compound, the melphalan analogue of 2-amino-2-
carboxylic-1,2,3,4-tetrahydronaphthalene (ACTN), improved
the therapeutic ratio by selectively increasing drug incor-
poration into tumour compared to normal murine haemo-
poietic cells (Ahmad et al., 1986).
Because of the interest in multiple myeloma at the Royal
Marsden Hospital, compounds that may reduce myelo-
suppression by being selectively incorporated into tumour
cells may provide additions or alternatives to high dose
melphalan in future clinical trials. This study was done to
investigate the role of the BCH-sensitive transport system in
human lymphoid tumour cell lines compared with normal
human bone marrow progenitors (GM-CFUJ) with a view to
testing compounds such as ACTN for selective activity
against myeloma cells taken from clinical biopsies.
Asynchronous cultures of CCRF-CEM (human T) (Foley
et al., 1965), HL60 (human myeloid) (Collins et al., 1977),
RPMI-8226 (human myeloma) (Matsuoko et al., 1967) and
MIT 1 (mouse T cell lymphoma) (Millar et al., 1988a) cell
lines were propagated by methods described previously
(Millar et al., 1988b).
Mononuclear cells (MNC) were prepared from bone
marrow or peripheral blood as before (Millar et al., 1988b).
Survival data were determined by exposing cells to different
concentrations of melphalan (0.1-1.Ojgml-1) dissolved in
Dulbecco's phosphate-buffered saline (PBSA) in the presence
or absence of 2.5mm BCH or 2.5mM L-leucine (Dufour et
al., 1985) for 1 h at 37°C before plating in semi-solid medium
for 2-3 weeks to allow for colony formation (Millar et al.,
1988b). Dose-response curves were constructed from the
mean survival values at each dose point from three separate
experiments. D1o and D1oo values were calculated from these
pooled data.
The incorporation and efflux of 14C-melphalan, labelled in
the alkylating moiety (0.1jICiml-1; specific activity
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10.9mCimm 1; 33.7jpCimg-1; Dr R. Engle, NCI, Bethesda,
MD, USA) with or without 2.5mm BCH or 2.5mM L-leucine
was made using methods described previously (Millar & Bell,
1987). Each experiment was done three times for each cell
line; examples of single experiments are shown in the text.
Efflux was measured in cells which had been equilibrated in
the presence or absence of 2.5 mM BCH followed by
exposure to PBSA with or without BCH in the surrounding
medium. The rate of efflux of 14C-melphalan was calculated
by comparing the c.p.m. in the cell pellets at equilibrium
(30min) with that for each subsequent time point.
The data in Table I confirm the observation that BCH
selectively inhibits the incorporation of melphalan into
murine tumour cells compared with MNC from normal
murine bone marrow (Vistica, 1980). BCH reduced the
incorporation of 14C-melphalan by approximately 50% into
MIT 1 cells and this was accompanied by an increase in cell
survival (Figure 1). In contrast to previously published
results (Dufour et al., 1985) BCH was without effect on the
incorporation or toxicity of melphalan to MNC from pooled
normal human bone marrow (three samples) (Table I).
However, unlike the effect in murine tumour cells, BCH also
failed to decrease the toxicity of melphalan to the human
malignant lymphoid cell lines, HL60, RPMI-8226 or CCRF-
CEM. Both RPMI-8226 and HL60 cells incorporated
approximately 90% as much melphalan in the presence of
BCH as in its absence. This small decrease was similar to
that seen in MNC from normal human bone marrow.
Although the incorporation of melphalan into CCRF-CEM
cells was decreased by 35% in the presence of BCH, this
decrease was not sufficient to detect any changes in clono-
genic survival (Figure 2). Furthermore, since the incor-
poration of melphalan into malignant plasma cells from a
patient with plasma cell leukaemia was reduced by only 20%
in the presence of BCH, it is unlikely that this decrease in
incorporation would be sufficient to permit any changes in
cell kill.
In contrast, L-leucine reduced 14C-melphalan uptake by
40-50% in RPMI-8226 and myeloma cells taken from
peripheral blood as well as CCRF-CEM cells, suggesting
that in human cells the BCH-insensitive transport system
provides the principal route by which melphalan is trans-
ported. Although reduction of 14C-melphalan uptake in
cultures of CCRF-CEM cells exposed simultaneously to L-
leucine was paralleled by a 5-fold increase in D1o for
melphalan, toxicity was not abolished. Furthermore, since L-
leucine failed to inhibit completely melphalan uptake into
either MNC from normal human bone marrow (Figure 3),
RPMI-8226 (Figure 3) or CCRF-CEM (Figure 2) cells in the
presence of BCH, it seems likely that other transport systems
provide a significant contribution towards the uptake of
melphalan into human haemopoietic cells.
Examination of the efflux of 14C-melphalan from MIT 1,
CCRF-CEM and RPMI-8226 cells pre-equilibrated with
melphalan with or without BCH showed that the differential
effect of BCH in decreasing melphalan toxicity towards
MIT 1 cells compared with CCRF-CEM and RPMI-8226
cells cannot be accounted for by changes in melphalan efflux
(Figure 4).
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Table I The effect of 2.5mM BCH or 2.5mM L-leucine on the incorporation of 14C-melphalan in lymphoid cells compared with changes in
clonogenic survival in vitro
Control 2.5mM BCH 2.5mM leucine
Cell type l4C-melphalana D10(ygml- 1) 14C-melphalan D10(pgml- 1) l4C-melphalan D10(pgml-)
RPMI-8226 5,104+ 178 0.43 4,542+8 0.45 3,058+ 100 0.88
HL60 4,971+236 0.42 4,764+120 0.43 n.a. n.a.
CCRF-CEM 6,398+709 0.28 4,212+41 0.31 1,591+194 1.42
Normal human bone marrow 2,505 +97 0.21 2,154+22 0.21 1,550+ 170 n.a.
Myeloma cells from peripheral blood 1,022+88 n.a. 832+46 n.a. 524+8 n.a.
Mouse MIT 1 9,496+ 145 0.08b 4,904+30 0.25b n.a. n.a.
Normal mouse bone marrow 2,053 +110 0.33 1,765+10 0.33 n.a. n.a.
aUptake of 14C-melphalan at equilibrium (c.p.m. per 107 cells+range). bD,0o values are shown because cell survival for MIT I cells is
biphasic (Figure 1).
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Figure 1 The effect of 2.5 mM BCH on the uptake of l4C-
melphalan into MIT cells (a) and the toxicity of melphalan to
MIT I cells (b). 0 melphalan alone; A melphalan + BCH.
Figure 2 The effect of 2.5mM BCH and/or 2.5mM L-leucine on
the uptake of 14C-melphalan into CCRF-CEM cells (a) and the
toxicity of melphalan in CCRF-CEM cells (b). 0 melphalan
alone; A melphalan +BCH; O melphalan +L-leucine; O
melphalan +BCH +L-leucine.
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It is clear from our data that generalisations based on the
contribution of the BCH-sensitive L transport system in
determining melphalan toxicity in murine tumours cannot be
extended to a range of human malignant haemopoietic
disorders from different haemopoietic lineages. The failure of
BCH to reduce melphalan cytotoxicity to both human bone
marrow progenitors and tumour cells suggests that these cell
types do not rely on the BCH-sensitive, leucine transport
system as the major route for melphalan incorporation.
However, in the present study, BCH was used at a concen-
tration of 2.5mM (Begleiter et al., 1979; Goldenberg et al.,
1979; Vistica, 1980) a value that greatly exceeds the Km for
BCH transport in a number of different cell types (Vistica,
1979). Further studies would be necessary to determine
whether melphalan transport is inhibited at lower concen-
trations of BCH.
While the exploitation of biochemical differences between
normal and malignant cells is likely to result in the synthesis
o Time (min) of compounds that may reduce normal tissue toxicity
x preferentially it is essential that such studies be done in
b hhuman as well as rodent cells hefore enterinn on a
programme of chemical synthesis. Based on our data, the
analogue, ACTN (Ahmad et al., 1986) is likely to be of
limited application against human haematological tumours.
Furthermore our results suggest that before this analogue or
others are tested against human tumour cells the presence of
the BCH-sensitive transport system should be checked first.
It is possible that this transport system is more prevalent in
'T' cell tumours than other lymphoid disorders. In view of
the simple correlation between changes in 14C-melphalan
uptake and changes in the clonogenic sensitivity of cells, the
use of radioactive tracer studies on clinical biopsies from
leukaemic patients with 'T' cell disorders may provide a
rapid assessment of whether this transport system can be
exploited in man. However, it is unlikely that there is
sufficient difference in melphalan transport between normal,
haemopoietic and myeloma cells to offer any therapeutic
benefit by utilising compounds that are transported by the
BCH-insensitive transport system in multiple myeloma in
Time (min) man.
Figure 3 The effect of 2.5mm BCH and/or 2.5mM L-leucine on
the uptake of 14C-melphalan into RPMI-8226 cells (a) and MNC
from normal human bone marrow (b). 0 melphalan alone; A
melphalan+ BCH; LI melphalan+ L-leucine; O melphalan+ We should like to thank the CRC/MRC and Leukaemia Research
BCH+L-leucine. Fund for supporting this work.
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Figure 4 The efflux of 14C-melphalan in the presence or absence of 2.5mm BCH from cells pre-equilibrated (30min) with
14C-melphalan, with or without 2.5mM BCH in MIT 1 (0), CCRF-CEM (A) and RPMI-8226 (El) cells. The range of data at
each time point for each set of conditions (i.e. pre-equilibration with 14C-melphalan followed by exposure to PBSA with or
without 2.5mm BCH; pre-equilibration with '4C-melphalan+2.5mM BCH followed by exposure to PBSA with or without 2.5mm
BCH) lay within the height of the designated symbol for each cell line.
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